Death from any cause at 30 days and rates of major bleeding similar with enoxaparin, placebo
WEDNESDAY, Dec. 28 (HealthDay News) -- For hospitalized, acutely ill medical patients, use of enoxaparin plus elastic stockings with graduated compressions, does not reduce the rate of death from any cause at 30 days, according to a study published in the Dec. 29 issue of the New England Journal of Medicine.
Ajay K. Kakkar, M.B., B.S., Ph.D., from the Thrombosis Research Institute in London, and colleagues investigated the effect of subcutaneous enoxaparin on the rate of death from any cause in hospitalized, acutely ill medical patients. A total of 4,171 participants were randomly allocated to receive enoxaparin, and 4,136 to placebo, for 10 ± 4 days; all participants wore elastic stockings with graduated compression. Death from any cause at 30 days following randomization was the primary efficacy end point, and the rate of major bleeding during, and 48 hours following, the treatment period was the primary safety outcome.
The investigators found that, at day 30, the rate of death from any cause was similar in the enoxaparin and placebo groups (4.9 and 4.8 percent, respectively; P = 0.83). There was no significant difference in the rate of major bleeding in the enoxaparin and placebo groups (0.4 and 0.3 percent, respectively; P = 0.35).
"The use of enoxaparin plus elastic stockings with graduated compression, as compared with elastic stockings with graduated compression alone, was not associated with a reduction in the rate of death from any cause among hospitalized, acutely ill medical patients," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Sanofi, which funded the study and manufactures enoxaparin.
Full Text (subscription or payment may be required)